Chemo-Pharma [CPL] vs Uniparts India [UNIPARTS] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemo-Pharma Laboratories Inc. wins in 6 metrics, Uniparts India Ltd. wins in 13 metrics, with 0 ties. Uniparts India Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma Laboratories Inc. | Uniparts India Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.22 | 17.45 | Chemo-Pharma Laboratories Inc. |
| Price-to-Book Ratio | 2.69 | 2.47 | Uniparts India Ltd. |
| Debt-to-Equity Ratio | 48.02 | 13.13 | Uniparts India Ltd. |
| PEG Ratio | 0.42 | 0.24 | Uniparts India Ltd. |
| EV/EBITDA | 13.60 | 11.68 | Uniparts India Ltd. |
| Profit Margin (TTM) | 6.53% | 11.99% | Uniparts India Ltd. |
| Operating Margin (TTM) | 11.52% | 15.89% | Uniparts India Ltd. |
| EBITDA Margin (TTM) | 11.52% | 15.89% | Uniparts India Ltd. |
| Return on Equity | 20.97% | 9.92% | Chemo-Pharma Laboratories Inc. |
| Return on Assets (TTM) | 11.26% | 7.52% | Chemo-Pharma Laboratories Inc. |
| Free Cash Flow (TTM) | $41.66M | $1.49B | Uniparts India Ltd. |
| Dividend Yield | N/A | 7.62% | N/A |
| 1-Year Return | -5.34% | 70.80% | Uniparts India Ltd. |
| Price-to-Sales Ratio (TTM) | 1.31 | 2.09 | Chemo-Pharma Laboratories Inc. |
| Enterprise Value | $5.40B | $20.77B | Uniparts India Ltd. |
| EV/Revenue Ratio | 1.52 | 1.92 | Chemo-Pharma Laboratories Inc. |
| Gross Profit Margin (TTM) | 24.93% | 67.48% | Uniparts India Ltd. |
| Revenue per Share (TTM) | $62 | $240 | Uniparts India Ltd. |
| Earnings per Share (Diluted) | $5.81 | $28.80 | Uniparts India Ltd. |
| Beta (Stock Volatility) | 0.28 | 0.49 | Chemo-Pharma Laboratories Inc. |
Chemo-Pharma Laboratories Inc. vs Uniparts India Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma Laboratories Inc. | 0.43% | -0.20% | -9.72% | 10.04% | -11.06% | -12.31% |
| Uniparts India Ltd. | 0.60% | 4.83% | 23.55% | 51.00% | 32.89% | 37.84% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma Laboratories Inc. | -5.34% | 232.23% | 82.57% | 325.71% | 1,271.09% | 1,271.09% |
| Uniparts India Ltd. | 70.80% | 14.88% | 361.33% | 307.85% | 307.85% | 307.85% |
Performance & Financial Health Analysis: Chemo-Pharma Laboratories Inc. vs Uniparts India Ltd.
| Metric | CPL | UNIPARTS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.62B | ₹22.69B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 97,700 | 63,280 |
| 90 Day Avg. Volume | 68,661 | 63,799 |
| Last Close | ₹70.50 | ₹663.65 |
| 52 Week Range | ₹52.67 - ₹87.75 | ₹335.00 - ₹672.60 |
| % from 52W High | -19.66% | -1.33% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹722.65 (Jul 31, 2023) |
| % from All-Time High | -44.92% | -8.16% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.40% | 0.35% |
| Quarterly Earnings Growth | 0.41% | 0.74% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.12% |
| Operating Margin (TTM) | 0.12% | 0.16% |
| Return on Equity (TTM) | 0.21% | 0.10% |
| Debt to Equity (MRQ) | 48.02 | 13.13 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹28.58 | ₹203.31 |
| Cash per Share (MRQ) | ₹0.05 | ₹69.26 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹1.66B |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹880.04M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 7.62% |
| Last 12-Month Dividend | ₹0.00 | ₹37.75 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma Laboratories Inc. vs Uniparts India Ltd.
| Metric | CPL (Apr 26, 2026) | UNIPARTS (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.22 | 17.45 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.42 | 0.24 |
| Price to Sales (TTM) | 1.31 | 2.09 |
| Price to Book (MRQ) | 2.69 | 2.47 |
| Market Capitalization | ||
| Market Capitalization | ₹4.62B | ₹22.69B |
| Enterprise Value | ₹5.40B | ₹20.77B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.52 | 1.92 |
| Enterprise to EBITDA | 13.60 | 11.68 |
| Risk & Other Metrics | ||
| Beta | 0.28 | 0.49 |
| Book Value per Share (MRQ) | ₹28.58 | ₹203.31 |
Financial Statements Comparison: Chemo-Pharma Laboratories Inc. vs Uniparts India Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | CPL (2025) | UNIPARTS (2025) |
|---|---|---|
| Revenue/Sales | 2.85B | 9.32B |
| Cost of Goods Sold | 2.07B | 4.07B |
| COGS % of Revenue | 72.6% | 43.7% |
| Gross Profit | 778.98M | 5.25B |
| Gross Margin | 27.4% | 56.3% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 300.69M | 918.94M |
| Operating Margin | 10.6% | 9.9% |
| EBITDA | 353.29M | 1.58B |
| EBITDA Margin | 12.4% | 16.9% |
| Pre-Tax Income | 392.47M | 1.14B |
| Pre-Tax Income % of Revenue | 13.8% | 12.3% |
| Income Tax | 79.24M | 262.70M |
| Income Tax % of Revenue | 2.8% | 2.8% |
| Net Income (Profit) | 313.23M | 880.04M |
| Profit Margin | 11.0% | 9.4% |
Balance Sheet & Liquidity Metrics
| Metric | CPL (2025) | UNIPARTS (2025) |
|---|---|---|
| Cash & Equivalents | 12.05M | 328.89M |
| Total Current Assets | 2.51B | 8.14B |
| Total Current Assets % of Revenue | 88.1% | 87.3% |
| Total Current Liabilities | 1.17B | 2.16B |
| Total Current Liabilities % of Revenue | 41.2% | 23.2% |
| Long-Term Debt | 109.50M | 263.82M |
| Long-Term Debt % of Revenue | 3.8% | 2.8% |
| Total Shareholders Equity | 1.49B | 8.87B |
| Retained Earnings | 1.08B | 8.55B |
| Retained Earnings % of Revenue | 37.9% | 91.7% |
| Property, Plant & Equipment | 48.61M | 2.57B |
Cash Flow Statement Comparison
| Metric | CPL (2025) | UNIPARTS (2025) |
|---|---|---|
| Operating Cash Flow | 277.99M | 1.66B |
| Operating Cash Flow % of Revenue | 9.8% | 17.8% |
| Capital Expenditures | -47.82M | -277.68M |
| Free Cash Flow | 41.66M | 1.49B |
| FCF Margin | 1.5% | 16.0% |
| Debt Repayment | -359.80M | -9.98M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | UNIPARTS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 60.18M | 45.10M |
| Float Shares | 17.41M | 15.04M |
| % Held by Insiders | 69.98% | 65.94% |
| % Held by Institutions | 0.00% | 3.88% |
| % Held by Public | 30.02% | 30.18% |
Dividend Analysis & Yield Comparison: Chemo-Pharma Laboratories Inc. vs Uniparts India Ltd.
| Metric | CPL | UNIPARTS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹37.75 |
| Last 12-Month Dividend Yield | N/A | 7.62% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹26.75 |
| 3-Year Avg Dividend Yield | N/A | 1.90% |
| 3-Year Total Dividends | ₹0.00 | ₹80.25 |
| Ex-Dividend Date | N/A | Feb 16, 2026 |